DOCSLIB.ORG

SOMMAIBE Le Sulfinpyrazone (Anturan)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
SOMMAIBE Le Sulfinpyrazone (Anturan) Canad. Med. Ass. J. 818 SMYTHE AND OTHERS: PLATELET ECONOMY April 10, 1965, vol. 92 SOMMAIBE Le sulfinpyrazone (Anturan), administr6 .i doses th6rapeutiques pendant une p&iode de plusieurs semaines, a entrain6 une survie prolong6e des plaquettes et un ralentisse- ment du roulement biologique, tout en n'affectant gu.re Ia coagulation du sang. Les modifications portant sur la survie des plaquettes et leurs roulement biologique provenaient d'une diminution de l'adh6rence des plaquettes. Ii est done possible de r6aliser une 6conomie sensible des plaquet- tes chez l'homme sans, pour autant, toucher .i Ia coagulation sanguine. Canad. Med. Ass. J. April 10, 1965, vol. 92 SMYTHE AND OTHERS: PLATELET ECONOMY 819 TABLE 1.-CoAGUlATIoN TESTS Mean (harmonic) Mean (geometric) Mean plasma dotting time prothrombin time thromboplastin Mean platelet (minutes) (seconds) time (seconds) adhesive index No No No No Subject** Age Diagnosis therapy Suif. therapy Suif. therapy Suif. therapy Suif. Si.60 M.I. 10.4 7.6 - - 12.5 12.4 1.10 1.05 An.59 R.A. 9.7 6.0 14.0 12.3 11.4 11.9 0.96 1.25 Ma.50 Gout - - - - - - - - So.60 S.gout - - 15.0 15.0 14.1 13.3 1.28 1.32 Mi.65 Myel. - - - - - - - 1.12 Na.54 M.I. 9.0 9.1 14.5 13.3 11.3 12.6 1.89 1.24 Sh.41 M.I. 12.0 8.1 14.0 15.0 10.1 11.4 1.31 0.96 Ha.23 Normal 9.1 11.7 13.0 13.0 11.5 16.3 1.32 1.48 liar.62 S.gout - - - 18.1 - - - 1.23 She.69 Gout 10.7 12.7 15.0 14.9 10.9 14.0 1.26 0.87 Bu.41 Phieb. 10.5 12.6 13.2 13.8 10.2 12.1 1.47 1.25 By.57 Gout 10.6 12.6 15.4 14.4 12.1 12.0 1.48 1.45 Cl.35 Gout 15.4 9.9 14.5 15.8 12.0 10.1 1.09 1.16 Cia.42 Gout 7.0 11.8 14.7 13.6 12.0 12.5 1.20 1.09 Ca.51 Gout 6.7 8.5 13.7 14.8 11.8 13.2 1.69 1.14 Hu.38 Gout 9.8 12.0 14.0 14.7 11.4 11.3 1.18 1.08 Co.51 Gout 8.7 12.8 14.9 14.3 11.8 9.0 1.42 1.24 Mar.57 MI. 10.7 7.4 14.6 14.3 10.9 15.6 1.23 1.02 Da.71 M.I. 9.2 11.2 14.5 13.0 17.1 12.0 1.08 1.06 Ro.36 Normal 12.5 10.5 14.3 13.4 13.4 10.2 1.12 1.14 Ja.45 Normal 9.9 10.5 13.5 13.3 11.5 11.1 1.51 1.32 Meanof means.9.76 10.15 14.30 14.22 11.58 12.07 1.325 1.184 Significance of differences between means* t 0.421 t 0.283 t 0.968 t 1.949 Subjects 1 - 17 p <0.7 p <0.8 p <0.4 p <0.1 All subjects t 0.170 t 1.013 t 0.371 t 2.309 p <1.0 P <0.4 p <0.8 p <0.05 M.I. = myocardial infarct; R.A. = rheumatoid arthritis; S. gout = secondary gout; Myel. = myeloproliferative disease; Phieb. = phlebitis. *Based on paired difference analysis. **Subjects Mar, Da, Ro and Ja received therapy for only four weeks or less. Cohen'2 using radioactive di-isopropyl fluorophos- the period of treatment (Table II). The four sub- phate (DFP32). Platelet turnover values were cal- jects who did not show an effect (Mar, Da, Ro culated on the basis of the average platelet count and Ja) had been given the drug for only a period during the period of the study, using a formula of four weeks or less prior to the study. One of recorded elsewhere.'1 these subjects (Mar) was studied again after being on the drug for four months. At that time Statiatical Canuiderations his platelet half-life value was 4.65 days, which is considerably longer than the pre-treatment value. The statistical considerations involved in the Platelet survival in the 17 subjects receiving the evaluation of data of this type have been described drug for a period longer than five weeks was over elsewhere." 10, . Since the same subjects were 40% longer than that seen in the pre-treatment studied during a "treatment" period and a "no period. Platelet turnover showed a similar trend. treatment" period, the analysis of the data was All but two of the subjects receiving the drug for by paired differences. a period of five weeks or longer showed a reduction in platelet turnover. The average reduction (based RESULTS on the exponential model) produced in these 17 There was no difference in the clotting time for subjects by sulfinpyrazone therapy was over 40%. the subjects during the "no treatment" and "treat- ment" periods (Table I). Similarly, neither the DIsCUsSION plasma thromboplastin time nor the prothrombin These studies show that sulfinpyrazone, which has time showed any consistent trend. Twelve of 18 a uricosuric effect, also has a considerable influence subjects showed lower platelet adhesiveness during on platelet economy. The change in platelet survi- the "treatment" period than during the "no treat- val is striking and the effect on platelet turnover ment" period and there was a significant difference greater than that which has been observed with between the means (Table I). There was a signffi- most other manipulative procedures.3' 14,15 Since, in cant reduction in the mean platelet count during their usual therapeutic doses, drugs commonly used the period of therapy. All but four of the 21 sub- to treat thrombosis, such as bishydroxycoumarin and jects showed a longer platelet survival time during heparin, do not exert so great an effect, the question 820 SMYTHE AND onmiis: PLATELET Canad. Med. Ass. 3. ECONOMY April 10, 1965, vol. 92 TABLE 11.-PLATELET SURVIVAL AND TURNOVER Mean Platelet survival (days) Platelet turnover (No./c.mm./day) platelet count (No./c.mm.) Exponential Gaussian Exponential Gaussian No No No No No Subject therapy Suif. therapy Suif. therapy Suif. therapy Sulf. therapy Suif. Si.218,000 320,000 3.655 5.034 10.877 13.192 41,340 44,060 20,040 24,260 An.280,000 256,000 2.809 4.137 10.695 11.629 69,090 42,890 26,180 22,010 Ma.220,000 178,000 2.978 3.424 10.153 11.038 51,210 36,030 21,670 16,130 So.118,000 96,000 3.610 4.881 10.899 12.899 22,660 13,630 10,830 7,450 Mi.750,000 622,000 3.736 4.339 10.703 11.803 139,150 99,360 70,070 52,700 Na.260,000 245,000 3.038 5.997 10.335 13.774 59,320 28,320 25,160 17,790 Sh.220,000 178,000 2.840 4.787 10.523 13.110 53,690 25,770 20,910 13,580 Ha.372,000 144,000 3.734 4.035 11.189 12.081 69,050 24,740 33,250 11,920 Har.220,000 155,000 6.745 8.285 14.183 19.088 22610 12970 15510 8120 She.173,000 124,000 3.366 4.047 10.838 11.590 35:620 21,240. 15,960 10,700 Bu.470,000 309,000 2.708 5.611 10.389 14.340 120,300 38,170 45,240 21,550 By.233,000 232,000 3.510 3.744 11.300 11.283 46,010 42,950 20,620 20,560 Cl.224,000 247,000 2.008 4.831 9.680 12.970 77,320 35,440 23,140 19,040 Cia.214,000 182,000 2.476 2.927 9.933 11.461 59,910 43,100 21,540 15,880 Ca.182,000 122,000 2.517 3.953 9.385 11.835 50,120 21,390 19,390 10,310 Ru.180,000 170,000 2.230 7.150 9.886 15.420 55,950 16,480 18,210 11,020 Co.246,000 212,000 2.766 4.120 10.402 11.650 61,650 35,670 23,650 18,200 Mar. 308,000 244,000 4.133 3.127 12.095 10.625 51,650 54,090 25,470 22,960 Da.207,000 233,000 4.013 3.785 11.698 11.286 35,750 42,670 17,700 20,650 Ro.204,000 206,000 3.059 2.767 10.453 10.150 46,220 51,600 19,520 20,300 Ja.366,000 304,000 3.536 3.461 11.008 11.060 71,750 60,880 33,250 27,490 Mean or mean of means. 269,800 223,100 3.308 4.497 10.792 12.489 59,065 37,688 25,110 18,696 Significance of differences between means* t 2.607 t 5.206 t 5.862 t 5.498 t 4.459 Subjects 1-17 p <0.02 p <0.001 p <0.001 p <0.001 p <0.001 All subjects.. t 2.823 t 3.979 t 4.316 t 4.606 t 4.192 p <0.02 p <0.001 p <0.001 p <0.001 p <0.001 *Based on paired difference analysis.
Load more

Recommended publications
  • Sulfinpyrazone 100Mg and 200Mg Tablets (Sulfinpyrazone)
    Prescribing information sulfinpyrazone 100mg and 200mg tablets (sulfinpyrazone) Presentation: Coated tablets agents, sulphonamides, penicillin, theophylline, phenytoin, non- indication: Chronic, including tophaceous gout; recurrent gouty steroidal antirheumatic drugs. arthritis; hyperuricaemia Pregnancy and lactation: Used with caution in pregnant women, Dosage and administration: Route of administration: Oral. Adults: weighing the potential risk against the possible benefits. It is not known 100-200mg daily increasing gradually (over the first two or three whether the active substance or its metabolite(s) pass into breast milk. weeks) to 600mg daily (rarely 800mg), and maintained until the For safety reasons mothers should refrain from taking the drug. serum urate level has fallen within the normal range. Maintenance Undesirable effects: Mild transient gastro-intestinal upsets, such dose may be as low as 200mg daily. Children: Paediatric usage as nausea, vomiting, diarrhea, gastro-intestinal bleeding and not established. ulcers, acute renal failure, salt and water retention, allergic skin contraindications: Acute attacks of gout. Gastric and duodenal reactions, leucopenia, thrombocytopenia, agranulocytosis, aplastic ulcer. Known hypersensitivity to sulfinpyrazone and other pyrazolone anaemia, hepatic dysfunction, jaundice and hepatitis. derivatives. Contra-indicated in patients with asthma, urticaria, or (Please refer to the Summary of Product Characteristics for acute rhinitis, severe parenchymal lesions of the liver or kidneys, detailed information) porphyria, blood dyscrasias, haemorrhagic diatheses overdose: Nausea, vomiting, abdominal pains, diarrhoea, Precautions and warnings: Used with caution in patients with hypotension, cardiac arrhythmias, hyperventilation, respiratory hyperuricaemia or gout, episodes of urolithiasis or renal colic, disorders, impairment of consciousness, coma, epileptic seizures, ensure adequate fluid intake and alkalinisation of the urine during oliguria or anuria, acute renal failure, renal colic.
    [Show full text]
  • New Zealand Data Sheet
    NEW ZEALAND DATA SHEET 1 PRODUCT NAME DICLOFENAC SANDOZ 25mg enteric coated tablet 50mg enteric coated tablet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each Diclofenac Sandoz 25 mg tablet contains Diclofenac Sodium 25mg Each Diclofenac Sandoz 50 mg tablet contains Diclofenac Sodium 50mg Tablets contain lactose. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM 25 mg Brown-yellow gastro-resistant film coated tablets, round, biconvex faced with a plain rim. Approximate tablet dimensions: diameter 6.1 to 6.3 mm; thickness 2.9 to 3.2 mm. Each tablet contains Diclofenac Sodium Ph Eur 25 mg. 50 mg Brown-yellow gastro-resistant film coated tablets, round, biconvex faced with a banded rim. Approximate tablet dimensions: diameter 8.0 to 8.3 mm; thickness 3.5 to 3.8 mm. Each tablet contains Diclofenac Sodium Ph Eur 50 mg. 4 CLINICAL PARTICULARS 4.1 Therapeutic indications Treatment of: • Inflammatory and degenerative forms of rheumatism - rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and spondylarthritis, painful syndromes of the vertebral column, non-articular rheumatism; • Acute attacks of gout; • Post-traumatic and post-operative pain, inflammation, and swelling, e.g. following dental or orthopaedic surgery; • Painful and/or inflammatory conditions in gynaecology, e.g. primary dysmenorrhoea or adnexitis; • As an adjuvant in severe painful inflammatory infections of the ear, nose, or throat, e.g. pharyngotonsillitis, otitis. In keeping with general therapeutic principles, the underlying Page 1 of 18 NEW ZEALAND DATA SHEET disease should be treated with basic therapy, as appropriate. Fever alone is not an indication. 4.2 Dose and method of administration Dosage Diclofenac Sandoz should only be prescribed when the benefits are considered to outweigh the potential risks.
    [Show full text]
  • Nonsteroidal Antiinflammatory Drugs and Acute Renal Failure in Elderly Persons
    American Journal of Epidemiology Vol. 151, No. 5 Copyright © 2000 by The Johns Hopkins University School of Hygiene and Public Health Printed In U.S.A. Ail rights reserved Nonsteroidal Antiinflammatory Drugs and Acute Renal Failure in Elderly Persons Marie R. Griffin,1'2 Aida Yared,3 and Wayne A. Ray1 Renal prostaglandin inhibition by nonsteroidal antiinflammatory drugs (NSAIDs) may decrease renal function, Downloaded from https://academic.oup.com/aje/article/151/5/488/117194 by guest on 27 September 2021 especially under conditions of low effective circulating volume. To evaluate the risk of important deterioration of renal function due to this effect, the authors performed a nested case-control study using Tennessee Medicaid enrollees aged £65 years in 1987-1991. Cases were patients who had been hospitalized with community- acquired acute renal failure; they were selected on the basis of medical record review of Medicaid enrollees with selected discharge diagnoses. Information on the timing, duration, and dose of prescription NSAIDs used, demographic factors, and comorbidity was gathered from computerized Medicaid-Medicare data files. Of the 1,799 patients with acute renal failure (4.51 hospitalizations per 1,000 person-years), 18.1% were current users of prescription NSAIDs as compared with 11.3% of 9,899 randomly selected population controls. After control for demographic factors and comorbidity, use of NSAIDs increased the risk of acute renal failure 58% (adjusted odds ratio = 1.58; 95% confidence interval (Cl): 1.34, 1.86). For ibuprofen, which accounted for 35% of NSAID use, odds ratios associated with dosages of £1,200 mg/day, >1,200-<2,400 mg/day, and £2,400 mg/day were 0.94 (95% Cl: 0.58, 1.51), 1.89 (95% Cl: 1.34, 2.67), and 2.32 (95% Cl: 1.45, 3.71), respectively (test for linear trend: p = 0.009).
    [Show full text]
  • WO 2010/099522 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 2 September 2010 (02.09.2010) WO 2010/099522 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 45/06 (2006.01) A61K 31/4164 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/4045 (2006.01) A61K 31/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2010/025725 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 1 March 2010 (01 .03.2010) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/156,129 27 February 2009 (27.02.2009) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, HELSINN THERAPEUTICS (U.S.), INC.
    [Show full text]
  • S Salsalate Tablets
    SALSALATE TABLETS CARDIOVASCULAR EFFECTS renal disease. If SALSALATE TABLETS therapy must be initiated, Rx Only Cardiovascular Thrombotic Events close monitoring of the patient’s renal function is advisable. Cardiovascular Risk Clinical trials of several COX-2 selective and nonselective NSAIDs Anaphylactoid Reactions • NSAIDs may cause an increased risk of serious cardiovascular of up to three years duration have shown an increased risk of As with other NSAIDs, anaphylactoid reactions may occur in thrombotic events, myocardial infarction, and stroke, which can serious cardiovascular (CV) thrombotic events, myocardial patients without known prior exposure to SALSALATE TABLETS. be fatal. This risk may increase with duration of use. Patients infarction, and stroke, which can be fatal. All NSAIDs, both COX-2 SALSALATE TABLETS should not be given to patients with the with cardiovascular disease or risk factors for cardiovascular selective and nonselective, may have a similar risk. Patients with aspirin triad. This symptom complex typically occurs in asthmatic disease may be at greater risk. (See WARNINGS and CLINICAL known CV disease or risk factors for CV disease may be at greater patients who experience rhinitis with or without nasal polyps, or TRIALS). risk. To minimize the potential risk for an adverse CV event in who exhibit severe, potentially fatal bronchospasm after taking • SALSALATE TABLETS is contraindicated for the treatment of patients treated with an NSAID, the lowest effective dose should be aspirin or other NSAIDs (see CONTRAINDICATIONS and perioperative pain in the setting of coronary artery bypass graft used for the shortest duration possible. Physicians and patients PRECAUTIONS - Preexisting Asthma). Emergency help should be (CABG) surgery (see WARNINGS Gastrointestinal Risk) should remain alert for the development of such events, even in sought in cases where an anaphylactoid reaction occurs.
    [Show full text]
  • Highlights of Prescribing Information
    HIGHLIGHTS OF PRESCRIBING INFORMATION -----------------------------CONTRAINDICATIONS-------------------------------------­ These highlights do not include all the information needed to use Patients with known hypersensitivity to natural or recombinant hirudins, IPRIVASK safely and effectively. See full prescribing information for and in patients with active bleeding and/or irreversible coagulation IPRIVASK. disorders (4). IPRIVASK® 15 mg (desirudin for injection), for subcutaneous injection -----------------------WARNINGS AND PRECAUTIONS-----------------------------­ Initial U.S. approval: 2003 • Hemorrhage: Bleeding can occur at any site during therapy with WARNING: SPINAL/EPIDURAL HEMATOMAS Iprivask. An unexplained fall in hematocrit or blood pressure should See Full Prescribing Information for complete boxed warning. lead to a search for a bleeding site. Avoid intramuscular injection as When neuraxial anesthesia (epidural/spinal anesthesia) or local bleeding and hematoma formation may result. (5.3). spinal puncture is employed, patients anticoagulated or • Increased Risk of bleeding with Renal Impairment: Dose reductions scheduled to be anticoagulated with selective inhibitors of by factors of three and nine are recommended for patients with thrombin such as Iprivask may be at risk of developing an moderate and severe renal impairment respectively (2.2). In addition, epidural or spinal hematoma which can result in long-term or daily aPTT and serum creatinine monitoring are recommended for permanent paralysis (5.1). patients with moderate
    [Show full text]
  • Chemmart Meloxicam
    Chemmart Meloxicam Capsules Meloxicam Consumer Medicine Information For a copy of a large print leaflet, Ph: 1800 195 055 What is in this leaflet Ask your doctor if you have any swelling of the feet or lips due to questions about why this medicine fluid build-up Read this leaflet carefully before has been prescribed for you. · You experience bleeding from the taking your medicine. Your doctor may have prescribed this stomach, gut or any other This leaflet answers some common medicine for another reason. bleeding questions about meloxicam. It does This medicine is available only with · You have had a stroke resulting not contain all the available a doctor©s prescription. from a bleed in the brain or have information. It does not take the a bleeding disorder place of talking to your doctor or How it works · You currently have a peptic pharmacist. Meloxicam belongs to a family of (stomach) ulcer All medicines have risks and medicines called Non-Steroidal Anti- · You are lactose intolerant (this benefits. Your doctor has weighed inflammatory Drugs (NSAIDs). medicine contains lactose) the risks of you using this medicine These medicines work by relieving · You have Crohn©s Disease or against the benefits they expect it pain and inflammation. Ulcerative Colitis will have for you. There is no evidence that this · You have severe liver or kidney Keep this leaflet with your medicine is addictive. problems medicine. · You are currently taking other You may want to read it again. medicines known as: sulfinpyrazone (used to treat Before you take this gout), fluconazole (used to treat medicine fungal infections) or certain What this medicine is sulfur antibiotics (e.g.
    [Show full text]
  • Information for the User Diclofenac / Omeprazole Modified-Release
    Package Leaflet: Information for the User Diclofenac / Omeprazole modified-release capsules, hard, 75 mg / 20 mg diclofenac sodium/omeprazole Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Keep this leaflet. You may need to read it again. If you have any further questions, please ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Diclofenac / Omeprazole modified-release capsules, hard, 75 mg / 20 mg is and what it is used for 2. What you need to know before you take Diclofenac / Omeprazole modified-release capsules, hard, 75 mg / 20 mg 3. How to take Diclofenac / Omeprazole modified-release capsules, hard, 75 mg / 20 mg 4. Possible side effects 5. How to store Diclofenac / Omeprazole modified-release capsules, hard, 75 mg / 20 mg 6. Contents of the pack and other information 1. What Diclofenac / Omeprazole modified-release capsules, hard, 75 mg / 20 mg is and what it is used for Diclofenac / Omeprazole modified-release capsules, hard, 75 mg / 20 mg contains two active ingredients in a single capsule. These active ingredients are diclofenac sodium (75 mg) and omeprazole (20 mg). Diclofenac is one of a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs) and is used to reduce pain and inflammation of joint disorders.
    [Show full text]
  • Gastro-Duodenal Ulcers Associated with the Use of Non-Steroidal Anti-Inflammatory Drugs: a Systematic Review of Preventive Pharmacological Interventions
    Gastro-duodenal Ulcers Associated with the Use of Technology Non-steroidal Anti- inflammatory Drugs: A Systematic Review Report of Preventive Issue 38 September 2003 Pharmacological Interventions Publications can be requested from: CCOHTA 600-865 Carling Avenue Ottawa, Ontario, Canada K1S 5S8 Tel. (613) 226-2553 Fax. (613) 226-5392 Email: [email protected] or download from CCOHTA’s web site: http://www.ccohta.ca Cite as: Rostom A, Dubé C, Jolicoeur E, Boucher M, Joyce J. Gastro-duodenal ulcers associated with the use of non-steroidal anti-inflammatory drugs: a systematic review of preventive pharmacological interventions. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2003. Technology report no 38. Reproduction of this document for non-commercial purposes is permitted provided appropriate credit is given to CCOHTA. CCOHTA is a non-profit organization funded by the federal, provincial and territorial governments. Legal Deposit - 2003 National Library of Canada ISBN: 1-894620-92-5 (print) ISBN: 1-894620-93-3 (electronic version) Publications Mail Agreement Number: 40026386 Canadian Coordinating Office for Health Technology Assessment Gastro-duodenal Ulcers Associated with the Use of Non-steroidal Anti-inflammatory Drugs: A Systematic Review of Preventive Pharmacological Interventions Alaa Rostom MD MSc FRCPC1 1 Catherine Dubé MD MSc FRCPC 1 Emilie Jolicoeur MD 2 Michel Boucher BPharm MSc 2 Janet Joyce MLS September 2003 ________________________ 1 University of Ottawa, Ottawa, Ontario 2 Canadian Coordinating Office for Health Technology Assessment, Ottawa, Ontario Reviewers These individuals kindly provided comments on this report. External Reviewers Isabelle Chabot, PhD Betsy Miller, BScPharm MSc Manager, Health Economics and Executive Director Outcomes Research Patient Access and Outcomes Research Merck Frosst Canada & Co.
    [Show full text]
  • New Zealand Data Sheet IBUPROFEN LIQUID CAPSULES
    New Zealand Data Sheet IBUPROFEN LIQUID CAPSULES Neo Health Ibuprofen liquid capsules 400mg 1 PRODUCT NAME Ibuprofen 400mg Liquid capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains Ibuprofen 400 mg. For full list of excipients, see section 6.1 3.PHARMACEUTICAL FORM Capsule, soft Natural transparent, oval shaped, soft gelatin capsule containing clear colourless liquid. imprinted with L 160 in Black edible ink. 4.CLINICAL PARTICULARS 4.1 Therapeutic indications This medical product is indicated in adults and children & adolescents 12 years of age and over for the symptomatic treatment of mild to moderate pain and/or inflammation associated with headache, migraine, tension headache, muscular pain, dental pain, period pain, sinus pain, back pain, arthritis pain, cold and flu symptoms. 4.2 Dosage and administration For oral use and short-term use only. Capsules should not be chewed. Undesirable effects may be minimized by using the lowest effective dose for the shortest possible duration necessary to control symptoms (see section 4.4) Adults and children & adolescents 12 years of age and over. Initial dose, one capsule with water. Then, if necessary, one capsule every six hours. Do not exceed six capsules (2400 mg) in any 24-hour period. If in children and adolescents between 12 and 18 years this medicinal product is required for 3 days, or if symptoms worsen a doctor should be consulted. If in adults the product is required for more than 3 days in the case of fever and 4 days for treatment of pain, or if the symptoms worsen the patient is advised to consult a doctor.
    [Show full text]
  • Vinblastine and Sulfinpyrazone Export by the Multidrug Resistance Protein MRP2 Is Associated with Glutathione Export
    British Journal of Cancer (2000) 83(3), 375–383 © 2000 Cancer Research Campaign doi: 10.1054/ bjoc.2000.1262, available online at http://www.idealibrary.com on Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export R Evers1,4, M de Haas1, R Sparidans2, J Beijnen2, PR Wielinga3, J Lankelma3 and P Borst1 1Division of Molecular Biology and Center of Biomedical Genetics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Pharmacy, Slotervaart Hospital, Louwesweg 6, 1066 EC Amsterdam, The Netherlands; 3Academic Hospital Vrije Universiteit, Department of Medical Oncology, Room BR232, PO Box 7057, 1007 MB Amsterdam, The Netherlands; 4Present address Georg-Speyer-Haus, Paul Ehrlich straße 42–44, 60596 Frankfurt am, Germany Summary The multidrug resistance proteins MRP1 and MRP2 are members of the same subfamily of ATP-binding cassette transporters. Besides organic molecules conjugated to negatively charged ligands, these proteins also transport cytotoxic drugs for which no negatively charged conjugates are known to exist. In polarized MDCKII cells, MRP1 routes to the lateral plasma membrane, and MRP2 to the apical plasma membrane. In these cells MRP1 transports daunorubicin, and MRP2 vinblastine; both transporters export reduced glutathione (GSH) into the medium. We demonstrate that glutathione transport in MDCKII-MRP1 cells is inhibited by the inhibitors of organic anion transporters sulfinpyrazone, indomethacin, probenecid and benzbromarone. In MDCKII-MRP2 cells, GSH export is stimulated by low concentrations of sulfinpyrazone or indomethacin, whereas export is inhibited down to control levels at high concentrations. We find that unmodified sulfinpyrazone is a substrate for MRP2, also at concentrations where GSH export is inhibited.
    [Show full text]
  • Ibuprofen 600 Mg Film- Coated Tablets
    Package leaflet: Information for the user You should discuss your treatment with your doctor or pharmacist before taking Ibuprofen if Ibuprofen 600 mg film- you: • have heart problems including heart failure, coated tablets angina (chest pain), or if you have had a heart attack, bypass surgery, peripheral Read all of this leaflet carefully before artery disease (poor circulation in the legs you start taking this medicine because it or feet due to narrow or blocked arteries), or contains important information for you. any kind of stroke (including ‘mini-stroke’ or - Keep this leaflet. You may need to read it transient ischaemic attack “TIA”). again. • have high blood pressure, diabetes, high - If you have any further questions, ask your cholesterol, or have a family history of heart doctor or pharmacist. disease or stroke, or if you are a smoker. - This medicine has been prescribed for you Effects on the kidneys only. Do not pass it on to others. It may Ibuprofen may cause problems with kidney harm them, even if their signs of illness are function even in patients who have not had the same as yours. kidney problems before. This may result in - If you get any side effects, talk to your swelling of the legs and may even lead to heart doctor or pharmacist. This includes any failure or high blood pressure in predisposed possible side effects not listed in this leaflet. individuals. See section 4. Ibuprofen may cause kidney damage especially What is in this leaflet in patients who already have kidney, heart or 1. What Ibuprofen is and what it is used for liver problems, or are taking diuretics or ACE 2.
    [Show full text]